Proficio Capital Partners LLC Has $218,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Proficio Capital Partners LLC cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 99.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 808 shares of the biopharmaceutical company's stock after selling 192,852 shares during the period. Proficio Capital Partners LLC's holdings in Alnylam Pharmaceuticals were worth $218,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ALNY. Park Square Financial Group LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $28,000. Whipplewood Advisors LLC raised its position in Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 71 shares during the period. Bessemer Group Inc. raised its position in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 69 shares during the period. Colonial Trust Co SC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $35,000. Finally, Washington Trust Advisors Inc. raised its position in Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 61 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the company's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer owned 48,948 shares in the company, valued at approximately $14,978,088. This represents a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Trading Up 0.2%

ALNY stock traded up $0.81 during midday trading on Friday, reaching $328.81. The stock had a trading volume of 666,674 shares, compared to its average volume of 894,988. The business has a fifty day simple moving average of $310.69 and a two-hundred day simple moving average of $274.03. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. The firm has a market cap of $42.87 billion, a price-to-earnings ratio of -157.33 and a beta of 0.23. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $333.70.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The company's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.16) EPS. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ALNY. UBS Group upped their target price on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Redburn Atlantic began coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a "buy" rating and a $353.00 target price on the stock. Truist Financial began coverage on Alnylam Pharmaceuticals in a research report on Monday. They issued a "buy" rating and a $385.00 target price on the stock. Bank of America upped their target price on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Finally, Wall Street Zen raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-three have assigned a buy rating to the company's stock. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $347.75.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.